BOULDER, Colo.--Xenometrix, a biotech firm here with proprietary gene expression profiling technology and genotoxicology technology, received a cash infusion that the company said it expects will meet its operating requirements for two months. The infusion is the result of a letter of intent regarding a license for recently announced European patents and a US application and patents in the field of probe arrays.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.